Trial Profile
A Phase II Study of Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jun 2013
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 16 Sep 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 22 Oct 2010 Planned end date changed from 1 Dec 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 30 Oct 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.